Design Therapeutics Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Design Therapeutics has a total shareholder equity of $261.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $269.6M and $8.3M respectively.
Anahtar bilgiler
0%
Borç/özkaynak oranı
US$0
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$261.02m |
| Eşitlik | US$261.24m |
| Toplam yükümlülükler | US$8.34m |
| Toplam varlıklar | US$269.58m |
Son finansal sağlık güncellemeleri
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Oct 04
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Jun 19Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Mar 15Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Nov 16Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Jun 06Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Feb 09Recent updates
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Oct 04Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Jun 19Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Mar 15Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Nov 16Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Jun 06Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Feb 09Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Oct 25Design Therapeutics GAAP EPS of -$0.27 misses by $0.02
Aug 08We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate
Jul 02Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Mar 18Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Dec 03Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Aug 18Design Therapeutics expands board of directors
Jun 07Design Therapeutics EPS misses by $0.24
May 10Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: DSGN's short term assets ($264.8M) exceed its short term liabilities ($6.4M).
Uzun Vadeli Yükümlülükler: DSGN's short term assets ($264.8M) exceed its long term liabilities ($1.9M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: DSGN is debt free.
Borcun Azaltılması: DSGN had no debt 5 years ago.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: DSGN has sufficient cash runway for more than 3 years based on its current free cash flow.
Tahmini Nakit Akışı: DSGN has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 39.2% each year